EFHD2调节NOX4/ROS通路启动糖代谢重编程促进乳腺癌进展的机制研究
作者单位:

川北医学院

基金项目:

1.四川省科技厅项目(24NSFSC5546);2.南充市科学技术局项目(20SXQT0333);3.大学生创新创业国家级项目(202310634020);4.大学生创新创业省级项目(202310634040)。


The study of the mechanism by which EFHD2 regulates the NOX4/ROS pathway to initiate glycometabolism reprogramming and promote breast cancer progression
Author:
Affiliation:

1.North Sichuan Medical College;2.North Sichuan Medical college

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [29]
  • | | | |
  • 文章评论
    摘要:

    目的 基于NOX4/ROS信号通路探讨EFHD2影响乳腺癌发生进展的作用机制。方法 将细胞分为NC-shRNA组和EFHD2-shRNA组,构建沉默EFHD2表达的慢病毒载体及其对照载体后转染乳腺癌细胞MDA-MB-23、MCF-7,qRT-PCR验证转染效率;CCK8检测细胞增殖活性;平板克隆实验检测细胞集落形成能力;划痕实验检测细胞迁移;Transwell实验检测细胞侵袭;流式细胞术检测细胞凋亡及ROS水平;qRT-PCR检测GLUT1、PDK1、PFK1、PKM2、PDH、LDH mRNA的表达;Western blot检测Cleaved caspase-3、MMP-2、NOX4蛋白的表达。 结果 与NC-shRNA组相比,EFHD2-shRNA组细胞中EFHD2的表达明显降低,细胞存活及其集落形成能力减弱;细胞凋亡率及促凋亡蛋白Cleaved caspase-3的表达升高;细胞迁移距离缩短,细胞侵袭数及促迁移及侵袭蛋白MMP-2的表达降低;乳酸及GLUT1、PDK1、PFK1、PKM2、LDH的水平降低,ATP及PDH的水平升高;流式结果表明沉默EFHD2后ROS水平降低,NOX4蛋白下调。结论 EFHD2可通过调节NOX4/ROS信号通路,抑制ROS生成,引起乳酸及葡萄糖堆积从而促进乳腺癌细胞凋亡,抑制细胞增殖、迁移及侵袭。

    Abstract:

    Objective To investigate the mechanism of EFHD2 affecting the occurrence and progression of breast cancer based on NOX4/ROS signaling pathway. Methods The cells were divided into NC-shRNA group and EFHD2-shRNA group. The lentiviral vector silencing EFHD2 expression and its control vector were constructed and transfected MDA-MB-23 and MCF-7 breast cancer cells. The transfection efficiency was verified by qRT-PCR.CCK8 assay was used to detect cell proliferation activity. Plate cloning assay was used to detect cell colony formation ability. Scratch test was used to detect cell migration. Transwell assay was used to detect cell invasion. Flow cytometry was used to detect apoptosis and ROS levels. qRT-PCR was used to detect the mRNA expression of GLUT1, PDK1, PFK1, PKM2, PDH, and LDH. Western blot was used to detect the expression of Cleaved caspase-3, MMP-2 and NOX4 proteins. Results Compared with NC-shRNA group, EFHD2 expression was significantly decreased in EFHD2-SHRNA group, and cell survival and colony formation ability were weakened. The apoptosis rate and the expression of pro-apoptotic protein Cleaved caspase-3 increased. The cell migration distance was shortened, the number of cell invasion and the expression of MMP-2, which promotes migration and invasion, were decreased. The levels of lactic acid and GLUT1, PDK1, PFK1, PKM2 and LDH decreased, while the levels of ATP and PDH increased. Streaming results showed that ROS levels were reduced and NOX4 protein was down-regulated after silencing EFHD2. Conclusion EFHD2 can inhibit ROS production by regulating NOX4/ROS signaling pathway, cause lactic acid and glucose accumulation, promote apoptosis of breast cancer cells, and inhibit cell proliferation, migration and invasion.

    参考文献
    [1] Zhang L, Chen W, Liu S, et al. Targeting Breast Cancer Stem Cells [J]. Int J Biol Sci, 2023, 19(2): 552-570.
    [2] Zannetti A. Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0 [J]. Int J Mol Sci, 2023, 24(3).
    [3] Waks A G, Winer E P. Breast Cancer Treatment: A Review [J]. Jama, 2019, 321(3): 288-300.
    [4] Riggio A I, Varley K E, Welm A L. The lingering mysteries of metastatic recurrence in breast cancer [J]. Br J Cancer, 2021, 124(1): 13-26.
    [5] Wang R, Zhu Y, Liu X, et al. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer [J]. BMC Cancer, 2019, 19(1): 1091.
    [6] Jiang J, Jiang S, Ahumada-Canale A, et al. Breast Cancer Screening Should Embrace Precision Medicine: Evidence by Reviewing Economic Evaluations in China [J]. Adv Ther, 2023, 40(4): 1393-1417.
    [7] Lee J. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC) [J]. J Clin Med, 2023, 12(4).
    [8] Donahue P M C, Mackenzie A, Filipovic A, et al. Advances in the prevention and treatment of breast cancer-related lymphedema [J]. Breast Cancer Res Treat, 2023, 200(1): 1-14.
    [9] Zhang W Z, Chen L L, Yang S, et al. Clinical characterizationof EFHD2 (swiprosin-1) in Glioma-associated macrophages and its role in regulation ofimmunosuppression [J]. Genomics, 2023, 115(5): 110702.
    [10] Fan C C, Tsai S T, Lin C Y, et al. EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis [J]. Redox Biol, 2020, 34: 101571.
    [11] Kang Y, Amoafo E B, Entsie P, et al. A role for platelets in metabolic reprogramming of tumor-associated macrophages [J]. Front Physiol, 2023, 14: 1250982.
    [12] Liu X, Song J, Zhang H, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance [J]. Cancer Cell, 2023, 41(2): 272-287.e9.
    [13] Tsai C H, Chuang Y M, Li X, et al. Immunoediting instructs tumor metabolic reprogramming to support immune evasion [J]. Cell Metab, 2023, 35(1): 118-133.e7.
    [14] Yang K, Wang X, Song C, et al. The role of lipid metabolic reprogramming in tumor microenvironment [J]. Theranostics, 2023, 13(6): 1774-1808.
    [15] Chelakkot C, Chelakkot V S, Shin Y, et al. Modulating Glycolysis to Improve Cancer Therapy [J]. Int J Mol Sci, 2023, 24(3).
    [16] Wu H, Huang H, Zhao Y. Interplay between metabolic reprogramming and post-translational modifications: from glycolysis to lactylation [J]. Front Immunol, 2023, 14: 1211221.
    [17] Li G, Choi J E, Kryczek I, et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy [J]. Cancer Cell, 2023, 41(2): 304-322.e7.
    [18] Ma Y, Zhang X, Han X, et al. PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming [J]. Mol Carcinog, 2023, 62(6): 866-881.
    [19] Wang P, Sun J, Sun C, et al. BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1 [J]. Cancer Biol Ther, 2023, 24(1): 2225884.
    [20] Vuadens F, Rufer N, Kress A, et al. Identification of swiprosin 1 in human lymphocytes [J]. Proteomics, 2004, 4(8): 2216-20.
    [21] Huh Y H, Oh S, Yeo Y R, et al. Swiprosin-1 stimulates cancer invasion and metastasis by increasing the Rho family of GTPase signaling [J]. Oncotarget, 2015, 6(15): 13060-71.
    [22] Tu Y, Zhang L, Tong L, et al. EFhd2/swiprosin-1 regulates LPS-induced macrophage recruitment via enhancing actin polymerization and cell migration [J]. Int Immunopharmacol, 2018, 55: 263-271.
    [23] Fan C C, Cheng W C, Huang Y C, et al. EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma [J]. Sci Rep, 2017, 7(1): 14617.
    [24] Wang R, Liang L, Matsumoto M, et al. Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer? [J]. Biomolecules, 2023, 13(2).
    [25] Liu Y, Sun Y, Guo Y, et al. An Overview: The Diversified Role of Mitochondria in Cancer Metabolism [J]. Int J Biol Sci, 2023, 19(3): 897-915.
    [26] Liu Y, Chen C, Wang X, et al. An Epigenetic Role of Mitochondria in Cancer [J]. Cells, 2022, 11(16).
    [27] Pe?uelas-Haro I, Espinosa-Sotelo R, Crosas-Molist E, et al. The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression [J]. Hepatology, 2023, 78(2): 416-433.
    [28] 张伟楠. 咪康唑通过抑制PI3K/Akt/NOX4通路诱导肺鳞癌细胞凋亡并增敏顺铂的机制研究 [D]. 2021.
    [29] Su X, Yang Y, Guo C, et al. NOX4-Derived ROS Mediates TGF-β1-Induced Metabolic Reprogramming during Epithelial-Mesenchymal Transition through the PI3K/AKT/HIF-1α Pathway in Glioblastoma [J]. Oxid Med Cell Longev, 2021, 2021: 5549047.
    相似文献
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文
分享
文章指标
  • 点击次数:193
  • 下载次数: 0
  • HTML阅读次数: 0
  • 引用次数: 0
历史
  • 收稿日期:2024-03-05
  • 最后修改日期:2024-05-10
  • 录用日期:2024-09-09
防诈骗提示!请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭